|
Volume 271, Number 25,
Issue of June 21, 1996
pp. 14773-14778
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Ceruloplasmin Enhances Smooth Muscle Cell- and Endothelial
Cell-mediated Low Density Lipoprotein Oxidation by a
Superoxide-dependent Mechanism*
(Received for publication, October 17, 1995, and in revised form, January 31, 1996)
Chinmay K.
Mukhopadhyay
,
Eduardo
Ehrenwald
and
Paul L.
Fox
From the Department of Cell Biology, Cleveland Clinic Research
Institute, Cleveland, Ohio 44195
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES
ABSTRACT
Cultured vascular smooth muscle cells (SMC) and
endothelial cells (EC) stimulate low density lipoprotein (LDL)
oxidation by free radical-mediated, transition metal-dependent
mechanisms. The physiological source(s) of metal ions is not known;
however, purified ceruloplasmin, a plasma protein containing 7 coppers,
oxidizes LDL in vitro. We now show that ceruloplasmin also
increases LDL oxidation by vascular cells. In metal ion-free medium,
human ceruloplasmin increased bovine aortic SMC- and EC-mediated LDL
oxidation by up to 30- and 15-fold, respectively. The maximal response
was at 100-300 µg ceruloplasmin/ml, a level at or below the unevoked
physiological plasma concentration. Oxidant activity was dependent on
protein structure as a specific proteolytic cleavage or removal of one
of the seven ceruloplasmin copper atoms inhibited activity. Three lines
of evidence indicated a critical role for cellular superoxide
(O 2) in ceruloplasmin-stimulated oxidation. First, the rate of
production of O 2 by cells correlated with their rates of LDL
oxidation. Second, superoxide dismutase effectively blocked
ceruloplasmin-stimulated oxidation by both cell types. Finally,
O 2 production by SMC quantitatively accounted for the observed
rate of LDL oxidation. To show this, the course of O 2
production by SMC was simulated by repeated addition of xanthine and
xanthine oxidase to culture medium under cell-free conditions. Neither
ceruloplasmin nor O 2 alone increased LDL oxidation, but
together they completely reconstituted the oxidation rate of
ceruloplasmin-stimulated SMC. These results are the first to show that
ceruloplasmin stimulates EC- and SMC-mediated oxidation of LDL and that
cell-derived O 2 accounts quantitatively for
metal-dependent, free radical-initiated oxidation of LDL by
these cells.
INTRODUCTION
Oxidative modification of low density lipoprotein
(LDL)1 by incubation with iron or copper
salts generates a particle with altered chemical properties including
elevated levels of lysophosphatidylcholine and oxidized lipids and
increased electrophoretic mobility (1). Besides inducing foam cell
formation in cultured macrophages (2), oxidized LDL has other
properties in vitro consistent with a pro-atherogenic
function, e.g., it increases macrophage residence in the
vessel wall by chemoattractant activity for monocytes (3), by inducing
cellular production of chemoattractants (4), and by enhancing monocyte
binding to EC (Ref. 5; see Ref. 6 for review). Oxidized LDL also is
chemotactic for SMC (7) and reduces EC wound-healing responses (8)
in vitro.
Although the presence of oxidized LDL in atherosclerotic lesions has
been established (9, 10), the mechanism(s) of oxidation in
vivo is unknown. LDL may be oxidized in the plasma and taken up by
the vessel wall, or it may be oxidized within the vessel wall by
cell-mediated processes. Oxidation of LDL by cells of the type found in
the vessel wall, including EC (11, 12), SMC (11, 13), and monocytic
cells (14, 15, 16) has been described. Cell-derived superoxide
(O 2) is required for oxidation of LDL by SMC (17), EC (18),
and adherent monocytic cells (16, 19), although conflicting results
have been reported for the latter two cell types (20, 21). LDL
oxidation by EC (12) and SMC (13) also requires exogenous transition
metal ions.
Given the absence of measurable free copper and iron in plasma and
interstitial fluids (22), recent attention has focused on the
identification of physiological metal-containing complexes that promote
LDL oxidation (23, 24, 25) and on metal ion-independent mechanisms of
oxidation (26, 27). We (28, 29) and others (30, 31) have investigated
the role of the copper-containing plasma protein ceruloplasmin in this
process. Ceruloplasmin is an acute phase reactant containing 7 copper
atoms and carrying about 95% of plasma copper (see Refs. 32 and 33 for
review). Ceruloplasmin has a well documented ``oxidase'' activity
capable of oxidizing aromatic amines and ferrous ions (32). This
activity is thought to be catalyzed by a 4-copper complex within
ceruloplasmin and accompanied by 4-electron reduction of O2
to H2O (34).
In addition to its oxidase activity, purified human ceruloplasmin
oxidatively modifies LDL as measured by multiple determinants of lipid
oxidation including formation of thiobarbituric acid
reacting-substances (TBARS), conjugated dienes, and lipid
hydroperoxides and by increased electrophoretic mobility (29). The
oxidant activity of ceruloplasmin is strongly dependent on protein
structure; incubation with Chelex-100 (which removes only one of seven
copper atoms) and proteolytic cleavage at a single site (into 115- and
19-kDa fragments) both suppress activity (29). We now present
evidence that intact human ceruloplasmin stimulates oxidative
modification of LDL by vascular cells and that this activity depends on
the cellular release of O 2.
EXPERIMENTAL PROCEDURES
Materials
Ceruloplasmin was purified from human plasma as
described (28). The resulting ceruloplasmin preparation was pure as
determined by oxidase specific activity (35), by an absorbance ratio
(610 nm/280 nm) greater than 0.045 (32), and by homogeneity according
to SDS-polyacrylamide gel electrophoresis and silver staining. Purified
ceruloplasmin was primarily the intact 132-kDa monomer but also
contained the 115- and 19-kDa proteolytic fragments of ceruloplasmin
also present in serum (about 10% of total by SDS-polyacrylamide gel
electrophoresis). Catalase, dimethylthiourea, glutathione, sodium
formate, superoxide dismutase, xanthine, xanthine oxidase, and all
assay reagents were from Sigma, and Chelex-100 was from Bio-Rad.
Cell Culture
EC were isolated from adult bovine aortas as
described (36), subcultured by trypsinization, and grown to confluence
in Dulbecco's modified Eagle's medium and Ham's F-12 medium
containing 5% fetal calf serum (Hyclone Laboratories, Logan, UT). SMC
were isolated by the explant method using intima-media of adult bovine
aortas (37). The cells were made quiescent in Dulbecco's modified
Eagle's medium containing 1 mg/ml gelatin for at least 24 h. SMC
proliferation was measured as incorporation of
[3H]thymidine into trichloroacetic acid-precipitable
material (36), the rate of protein synthesis by SMC was measured as
incorporation of [3H]leucine into trichloroacetic
acid-precipitable material, and EC migration was measured by the
razor-wound assay as described previously (8). Human aortic EC cultured
on a fibronectin-coated (1 µg/cm2) surface, and human
aortic SMC were used in some experiments.
Lipoprotein Methods
Human LDL (density = 1.019-1.063
g/ml) was prepared by sequential ultracentrifugation from freshly
drawn, citrated plasma to which EDTA was added before centrifugation
(38). Before use, LDL was dialyzed at 4 °C against saline and
incubated with cell cultures in serum- and transition metal-free RPMI
1640 medium at 37 °C. LDL oxidation was determined as TBARS in the
conditioned medium and expressed as nmol malondialdehyde-equivalents/mg
LDL cholesterol. LDL oxidation was also measured as the formation of
conjugated dienes (39), total lipid peroxide content (40), and
conversion of phosphatidylcholine to lysophosphatidylcholine by solvent
extraction, thin layer chromatography, and Coomassie Blue staining
(41). Lipoprotein-deficient serum (LPDS; density > 1.25) was
prepared by ultracentrifugation of human plasma (38).
Other Methods
Superoxide production by cells (or by a
xanthine/xanthine oxidase generating system) was measured
spectrophotometrically by Cu/Zn-superoxide dismutase (SOD)-inhibited
reduction of cytochrome c (42). Cultured cells were
incubated in RPMI 1640 medium (without phenol red dye) with 3 × 10 5 M cytochrome c.
O 2-specific reduction of cytochrome c was
determined as the difference in absorbance at 550 nm between dishes
incubated ± SOD (100 units/ml). Cell-free dishes were used as
controls.
RESULTS
Effect of Human Ceruloplasmin on SMC- and EC-mediated LDL
Oxidation
The ability of human ceruloplasmin to promote LDL
oxidation by bovine aortic SMC and EC was investigated. LDL and
purified human ceruloplasmin were added to confluent cell cultures in
serum- and transition metal-free RPMI 1640 medium. Ceruloplasmin
stimulated SMC-mediated oxidation, measured as TBARS, from less than 1 to about 30 nmol malondialdehyde/mg cholesterol (Fig.
1A). The activation curve was sigmoidal with
half-maximal activity at 25-50 µg/ml and maximal oxidation at 100 µg/ml, a concentration below the mean unevoked plasma concentration
of 300 µg/ml. Ceruloplasmin at concentrations up to 300 µg/ml did
not alter the cellular rate of protein synthesis as measured by
[3H]leucine uptake. Ceruloplasmin-stimulated oxidation of
LDL was confirmed by three other chemical measures of LDL oxidation. In
the presence of SMC, a maximal amount of ceruloplasmin increased: (i)
the level of conjugated dienes in LDL from 0.04 to 0.12 absorbance
units (A234 nm), (ii) the amount of lipid peroxides from
0.0 to 0.7 µmol/mg LDL cholesterol, and (iii) the
lysophosphatidylcholine content of LDL from 10 ± 8 to 260 ± 20 µg
of lysophosphatidylcholine/mg LDL cholesterol (not shown). Furthermore,
LDL oxidized by the combined presence of ceruloplasmin and bovine SMC
had two biological activities that have been described for metal
ion-oxidized LDL (8, 43); it stimulated SMC proliferation (measured by
[3H]thymidine uptake) by about 75%, and almost
completely inhibited EC migration (measured by the razor-wound assay
(8)) with a half-maximal inhibition at 100 µg LDL cholesterol/ml (not
shown). Ceruloplasmin also stimulated LDL oxidation by bovine aortic EC
but to a lesser extent than by SMC (Fig. 1A). In multiple
independent experiments, the maximal ceruloplasmin-stimulated oxidant
activity of EC was 15-50% of that of SMC. Similar enhancement of
oxidation by ceruloplasmin was seen with aortic SMC and EC derived from
adult human tissue; the maximal oxidation (at 100 µg/ml of
ceruloplasmin) by human SMC was 18-22 nmol malondialdehyde/mg
cholesterol, and stimulation by human EC was generally 50-75% of that
of SMC (not shown).
Fig. 1.
Stimulation of cell-mediated LDL oxidation by
intact ceruloplasmin. A, bovine aortic SMC ( ), EC ( ),
or cell-free wells ( ) were incubated with LDL and ceruloplasmin for
24 h in RPMI 1640 medium. Lipoprotein oxidation was determined as
TBARS. B, SMC were incubated with LDL in the presence ( )
or the absence ( ) of 100 µg of ceruloplasmin. Similarly, EC
cultures were incubated with LDL in the presence ( ) or the absence
( ) of ceruloplasmin. LDL incubated with ceruloplasmin in cell-free
wells served as controls (×). C, SMC were incubated for
24 h with LDL and 100 µg/ml ( ) or 500 µg/ml ( ) of
ceruloplasmin in the presence of up to 10% LPDS. D,
purified human ceruloplasmin was proteolytically modified by incubation
with partially purified metalloproteinase isolated during ceruloplasmin
purification (28, 29). After 22 h at 37 °C in 25 mM
Tris-HCl, 10 mM CaCl2, pH 6.6, ceruloplasmin
was completely modified to 115- and 19-kDa fragments (by silver-stained
SDS-polyacrylamide gel electrophoresis gels, not shown). Ceruloplasmin
was also incubated with Chelex-100 beads for 4 h at 23 °C, and
the supernatant taken after centrifugation. LDL was incubated for
20 h at 37 °C with intact ( ), protease-treated (×), or
Chelex 100-treated ( ) ceruloplasmin.
A time course experiment using aortic SMC showed a 2-3-h lag followed
by a nearly linear increase in ceruloplasmin-stimulated oxidation of
LDL for at least 24 h (Fig. 1B). The lag before the
appearance of detectable amounts of TBARS in EC was longer, about
10 h, and the rate of oxidation during the linear phase was less
than half of that seen with SMC. The longer lag phase in EC may be due
to its lower rate of production of reactive oxygen intermediates (see
below), and consequently slower destruction of the antioxidants within
LDL believed to be responsible for the observed lag period (39).
Ceruloplasmin by itself, i.e., in the absence of cells, only
slightly increased LDL oxidation (Fig. 1, A and
B). This observation was consistent with our earlier results
showing that ceruloplasmin oxidized LDL in phosphate-buffered saline
but that proteins and amino acids blocked its activity (29). The
ability of cultured cells to overcome the inhibition by amino acids in
the culture medium indicated that SMC and EC cells may supply an
additional factor(s) required for ceruloplasmin-stimulated LDL
oxidation under these conditions. The well known nonspecific
antioxidant activity of proteins (44, 45) raises questions on the
physiological relevance of the stimulation of cellular oxidation of LDL
by ceruloplasmin. However, LPDS (used instead of serum to minimize the
complicating presence of lipoproteins), at concentrations as high as
10%, inhibited the oxidant activity of 100 µg/ml ceruloplasmin by
only 30%, and no inhibition of 500 µg/ml ceruloplasmin was observed
(Fig. 1C).
Treatment of ceruloplasmin with Chelex-100 removes one of seven copper
atoms and suppresses oxidant activity under cell-free conditions (29).
The results in Fig. 1D showed that pre-treatment of
ceruloplasmin with Chelex-100 totally blocked its ability to support
SMC-mediated (and EC-mediated, not shown) LDL oxidation. Ceruloplasmin
was subjected to proteolytic modification by incubation with a
partially purified preparation of the metalloproteinase separated from
ceruloplasmin during its purification (28). The treatment modified the
intact 132-kDa ceruloplasmin molecule to a complex of 115- and 19-kDa
degradation fragments. Proteolytically modified ceruloplasmin did not
stimulate SMC-mediated (and EC-mediated, not shown) LDL oxidation (Fig.
1D).
Role of Superoxide in Ceruloplasmin-stimulated LDL Oxidation by
Cells
Several laboratories have shown evidence that cellular
release of O 2 is required for metal ion-dependent,
EC- and SMC-mediated LDL oxidation (18, 42). In those studies
transition metals were supplied either as free iron or copper in the
culture medium. We therefore examined the role of O 2 in
ceruloplasmin-stimulated cell oxidation processes. The rate of
O 2 production by confluent bovine EC and SMC cultures was
measured at 15 min intervals by spectrophotometric measurement of
superoxide dismutase-inhibited reduction of cytochrome c.
The generation rate by SMC cultures was linear for 60 min with a
production rate of 2.30 nmol/well/h. This rate was 85% higher than
that by EC, which had a rate of 1.25 nmol/well/h. The level of LDL
oxidation (measured as TBARS) by SMC was about 105% higher than that
by EC providing correlative evidence for a relationship between
O 2 production and LDL oxidation by these cell types. A similar
relationship was seen for human aortic EC and SMC (not shown) and has
been described in multiple isolates of monkey SMC (42).
To further address the role of O 2 production in
ceruloplasmin- and cell-mediated oxidation, inhibition by
scavengers of O 2 and other reactive oxygen species was
examined. Cu/Zn-SOD blocked about 80% of ceruloplasmin-stimulated
oxidation by SMC cultures (Fig. 2A). Because
dismutation of O 2 releases H2O2, we
also added catalase to eliminate the latter species. Although catalase
alone was not an effective inhibitor, SOD and catalase in combination
blocked all LDL oxidation. Essentially identical results were seen in
human aortic SMC and in human and bovine aortic EC (not shown). Heat
treatment completely inactivated SOD (as shown by measuring O 2
production by the xanthine/xanthine oxidase system), and the
inactivated enzyme did not reduce ceruloplasmin-stimulated oxidation by
SMC, even in the presence of catalase. Jessup et al. (21)
have suggested that heat inactivation of SOD may release free metal
ions that exert oxidant activity and thereby mask antioxidant activity.
To test this possibility, heat-inactivated SOD was subsequently treated
with Chelex-100 to remove free divalent metal ions and was found to
give the same results as heat-inactivated SOD. Three hydroxyl radical
scavengers, mannitol, glutathione, and sodium formate, did not
significantly reduce ceruloplasmin-stimulated LDL oxidation by SMC.
However, dimethylthiourea, also a hydroxyl radical scavenger, was
effective. At least two possibilities are consistent with these data:
(i) hydroxyl radical is required for LDL oxidation under
these conditions, but only dimethylthiourea has sufficient scavenging
activity, or (ii) hydroxyl radical is not required for
oxidation, and dimethylthiourea exerts its inhibitory activity by a
distinct pathway. The second scenario is supported by the observation
that dimethylthiourea covalently interacts with O 2 (46). We
confirmed that dimethylthiourea blocked O 2 production by
xanthine and xanthine oxidase (not shown).
Fig. 2.
Effect of free radical inhibitors on
ceruloplasmin-stimulated, cell-mediated LDL oxidation. A,
SMC were incubated with LDL (widely striped bar), LDL plus
100 µg/ml of ceruloplasmin (black bar), and LDL plus
ceruloplasmin and inhibitors of lipid oxidation (densely striped
bars) for 24 h. The inhibitors used were Cu, Zn-SOD (100 units/ml), catalase (1000 units/ml), mannitol (20 mM),
glutathione (reduced, 50 mM), sodium formate (100 mM), and dimethylthiourea (10 mM). SOD was
heated at 95 °C for 10 min (SOD (heated)), and activity
loss was shown using a O 2-generating system containing
xanthine and xanthine oxidase. B, in a time course
experiment SMC were incubated with LDL and 100 µg/ml ceruloplasmin,
and either 100 units/ml SOD ( ) or SOD plus 1000 units/ml catalase
( ) added at the time indicated. In control wells, SMC were incubated
with LDL in the absence of ceruloplasmin (shaded circle and
shaded square) or with ceruloplasmin (Cp) but in
the absence of any inhibitor ( , ).
O 2 may be necessary for initiating lipid peroxidation, in
which case it may be needed only during the beginning of the reaction
period; alternatively, O 2 may be necessary for subsequent
propagation reactions, which may require its continuous presence. To
examine the temporal requirement for O 2, SOD or SOD plus
catalase were added to bovine aortic SMC after initiation of oxidation
by the addition of ceruloplasmin (Fig. 2B). After an
incubation interval totaling 24 h, ceruloplasmin-stimulated LDL
oxidation was measured. SOD was found to block subsequent LDL
oxidation, independent of its time of addition. This result shows that
the early presence of O 2 is not sufficient to initiate
oxidation at maximal levels, but rather that the continuous generation
of O 2 is required.
Reconstitution of SMC Oxidant Activity by Ceruloplasmin and
Superoxide
A cell-free reconstitution strategy was used to
determine if the cell contribution of O 2 can account
quantitatively for cellular oxidation of LDL by SMC in the presence of
ceruloplasmin. Xanthine and xanthine oxidase were used under aerobic
conditions to generate O 2. In this system, xanthine is
oxidized to urate by xanthine oxidase with consequent reduction of
O2 to O 2. We first developed an appropriate
protocol that mimicked the cellular environment. Concentrations of
xanthine and xanthine oxidase were chosen such that the rate of release
of O 2 closely approximated that by cultured SMC (about 6 nmol
in 3 h). Under these conditions, the rate of O 2
production by the generating system was nearly constant for up to 2-3
h and then gradually dropped off, presumably due to enzyme inactivation
under these conditions. The rate of O 2 production by cultured
SMC was constant for at least 24 h. A single addition of
xanthine/xanthine oxidase to SMC in the presence of ceruloplasmin
increased LDL oxidation during a 24-h interval almost 3-fold, a
stimulation much less than the 9-fold increase by ceruloplasmin-treated
SMC (Fig. 3A). When the O 2
generating system was repeatedly added at 3-h intervals for 24 h,
LDL oxidation was increased about 8-fold to an extent closely
approximating SMC-mediated oxidation. This amount of O 2 (given
according to the same regimen) was completely inactive in the absence
of ceruloplasmin. Application of a large ``burst'' of O 2 (by
a single addition of the same amount of xanthine and xanthine oxidase
used in the multiple addition regimen) did not increase LDL oxidation
beyond that found with the single small dose. Thus early addition of
O 2, even at high levels, is not sufficient to induce maximal,
long-term oxidation (confirming the results of Fig. 2B).
More importantly, the results show quantitatively that the amount of
O 2 produced by SMC is sufficient to account for the observed
ceruloplasmin-dependent oxidation by the cells.
Fig. 3.
Reconstitution of SMC-mediated LDL oxidation
by ceruloplasmin and superoxide and the role of stable SMC products.
A, LDL was incubated for 24 h (lane 1) under
cell-free conditions (widely striped bars). O 2 was
generated under the same conditions by the addition of 1 mM
xanthine and 0.15 mM xanthine oxidase at the start of the
incubation (lanes 2 and 5). This
xanthine/xanthine oxidase (X/XO) system was found to
approximate the rate of O 2 release by SMC (about 6 nmol in
3 h). To simulate continuous release of O 2 by SMC, 0.15 milliunit of xanthine oxidase was resupplied at 3-h intervals
(lanes 3 and 6). An initial burst of 45-50 nmol
of O 2 (during a 30-min interval) was generated by the addition
of 0.1 mM xanthine and 1 milliunit of xanthine oxidase
(lane 7). Ceruloplasmin (100 µg/ml) was added to the
cell-free incubation tubes (lanes 4-7) and also to cultured
SMC (lane 8, densely striped bar). A schematic
representing the time course of O 2 generation is shown at
top. B, SMC were allowed to condition RPMI 1640 medium for 24 h. The conditioned medium was subsequently incubated
for 24 h with LDL (lane 1) under cell-free conditions
(widely striped bars). To LDL-containing conditioned medium
was added 100 µg/ml of ceruloplasmin (Cp, lanes
2, 4, 5, and 6). In some wells 1 mM xanthine and 0.15 milliunit of xanthine oxidase were
added repeatedly as in A to simulate O 2 generation
by SMC (lanes 3-6). SOD (lane 5, 100 units/ml)
and catalase (lane 6, 1000 U/ml) were also added. Wells containing SMC
(densely striped bars) were incubated for 24 h in the
absence (lane 7) or the presence (lane 8) of
ceruloplasmin.
Although these studies show the continuous requirement for the
short-lived O 2 species, we also investigated the role of
long-lived cellular products on LDL oxidation. Conditioned medium taken
from SMC after a 24-h incubation did not cause significant oxidation of
LDL either by itself or in the presence of ceruloplasmin, indicating
that stable cell products do not contribute significantly to
cell-mediated oxidation by ceruloplasmin (Fig. 3B).
Likewise, the addition of xanthine and xanthine oxidase to conditioned
medium did not enhance LDL oxidation. Simultaneous addition of
ceruloplasmin and the O 2 generating system (added at 3-h
intervals) to SMC-conditioned medium resulted in oxidation to nearly
the same extent as that induced by ceruloplasmin in the presence of SMC
cultures. Thus inhibitory agents are not present in SMC-conditioned
medium, and oxidant activity of SMC is effectively reconstituted by
ceruloplasmin and O 2 under conditions very similar to those
present in cultured cells.
DISCUSSION
Lipoprotein oxidation occurs by both metal
ion-dependent and -independent pathways in vitro
(47). Given the virtual absence of free copper and iron in plasma and
other biological fluids (22), the elucidation of protein-bound metal
ions that catalyze LDL oxidation represents an important goal in
understanding mechanisms of metal ion-dependent oxidation
processes in vivo. Our results indicate that human
ceruloplasmin at subphysiological concentrations can substitute for
free metal ions in stimulating LDL oxidation by vascular cells.
Ceruloplasmin copper is required for the activity because pretreatment
with Chelex-100 is completely inhibitory. The treatment removes only
one of the seven ceruloplasmin copper atoms (29), indicating that this
specific copper is required for cell-mediated oxidation. Because
treatment with Chelex-100 does not diminish ceruloplasmin amine oxidase
activity (29), these results also indicate that oxidase activity is not
sufficient to induce cell-mediated LDL oxidation. Cleavage of
ceruloplasmin into 115- and 19-kDa fragments completely inactivates the
protein. The requirement for intact protein may explain the reported
inability of ceruloplasmin to stimulate LDL oxidation by monocytic
cells unless ceruloplasmin was pretreated with acid (and copper
released, presumably by denaturation) (30). Because about 10% of the
ceruloplasmin in plasma is present as the proteolytically modified
isoform, it is tempting to speculate that proteolysis represents a
physiological mechanism regulating oxidant activity.
Under the conditions of these experiments, ceruloplasmin did not
significantly oxidize LDL in the absence of cells. This result
contrasts with previous results showing that ceruloplasmin by itself is
sufficient to oxidize LDL (when co-incubated in phosphate-buffered
saline) (29). This apparent discrepancy is explained by our previous
results that show that several proteins and also a mixture of amino
acids inhibit ceruloplasmin oxidant activity (29). Thus the inhibition
of LDL oxidation by the amino acids in RPMI 1640 (and perhaps other
medium components) is consistent with our previous observations using
ceruloplasmin and with observations by others using free metal ion
systems (44, 48). Because oxidation does occur in the presence of
either SMC or EC, these results also suggest that a critical factor(s)
provided by the cells is essential for ceruloplasmin-stimulated LDL
oxidation under these conditions. The high rate of LDL oxidation in the
presence of 10% LPDS contrasts with a recent observation that 6%
serum blocked almost 90% of the oxidation induced by murine
macrophages in the presence of 10 µM iron complexed to
nitriloacetic acid (45). We have not yet resolved whether the different
results are due to higher oxidant activity of ceruloplasmin compared
with the iron complex, higher activity of EC and SMC compared with
murine macrophages, or lower antioxidant activity of LPDS compared with
heat-inactivated serum. That ceruloplasmin-stimulated oxidation occurs
in the presence of 10% LPDS (and a fibronectin matrix for human EC)
suggests that this process may also occur under physiological
conditions.
Three experimental avenues indicate that cell-derived O 2 is a
critical factor necessary for ceruloplasmin-stimulated LDL oxidation by
vascular cells. First, the rate of production of O 2 by SMC was
twice that of EC, consistent with their differential rates of LDL
oxidation. This result agrees with previous results showing that cells
that oxidize LDL also secrete O 2 and that the rate of
O 2 production by a particular cell isolate correlates with its
ability to oxidize LDL (18, 42). Second, the addition of SOD
effectively blocked ceruloplasmin-stimulated LDL oxidation by both SMC
and EC. This result is also consistent with published reports of
inhibition of cell-mediated LDL oxidation by SOD or by inhibition of
O 2 production by elimination of L-cystine from the
medium (49). We now add a third line of evidence in support of the role
of O 2 in cell-mediated oxidation, namely, that the measured
rate of O 2 production by cells can quantitatively account for
the level of oxidation observed (in the presence of ceruloplasmin).
Repeated addition of xanthine and xanthine oxidase to simulate
continuous O 2 production by SMC in the presence of
ceruloplasmin and LDL completely reconstituted the oxidation rate of
SMC.
Although our results clearly indicate a role for O 2 in
ceruloplasmin-stimulated oxidation by EC and SMC, its reported role in
free metal ion-stimulated cell oxidation processes is controversial
(see Ref. 50 for review). The role of O 2 in SMC oxidation of
LDL has not been extensively investigated, but Heinecke et
al. (42) have shown that LDL oxidation is inhibited by SOD and
that a correlation exists between O 2 production and LDL
oxidation by several isolates of monkey SMC. The role played by
O 2 in EC oxidation of LDL is not clear because oxidation
has been reported to be not inhibited (51), slightly inhibited (20),
and completely inhibited (18) by SOD. The role of O 2 in
monocytic cell oxidation of LDL is also controversial (16, 19, 21). One
limitation of most of these studies is the dependence on a single
approach, i.e., inactivation of O 2 by SOD. Thus the
reported discrepancies may be due to variable activities of SOD
preparations (which upon partial denaturation exhibit oxidant activity
(21)) or alternatively may be due to differences in the cell isolates
used, in the specific media components, or in the preparation of
LDL.
The mechanism(s) of superoxide- and metal ion-dependent
oxidation is not known with certainty and has been an area of intense
investigation for many years. By analogy to previous work, multiple
mechanisms of superoxide- and ceruloplasmin-dependent oxidation
should be considered including: (i) the Fenton reaction in which
O 2 and H2O2 causes metal ion-dependent
production of highly reactive OH·, (ii) recycling of the
oxidation state of the oxidant copper by reduction by
O 2, (iii) O 2-dependent release of
copper from ceruloplasmin analogous to the release of Fe2+
from ferritin (52, 53), (iv) formation of a putative ``percupryl
ion'', i.e., a Cu2+/O 2 radical
analogous to the proposed perferryl ion (54), or (v)
O 2-mediated oxidation of Cu2+ to the powerful
oxidant Cu3+ (55). The first of these mechanisms is
unlikely because our studies with catalase indicate that hydrogen
peroxide is not required for LDL oxidation. Additional work will be
necessary to determine if one of the remaining mechanisms is operative.
The possible requirement for interaction of ceruloplasmin with
receptors on vascular cells or with LDL also remain key unanswered
issues.
According to one theory of atherosclerosis, oxidation of LDL within the
wall of major arteries has a key and causative role in the onset and
progression of the disease (6). According to our results,
co-localization of O 2, ceruloplasmin, and LDL in the same
region of the vessel wall would be consistent with the oxidation of the
latter. Studies in Watanabe hyperlipemic rabbits show that oxidized LDL
is found in macrophage-rich early lesions and is associated with
intimal and medial SMC, as well as the necrotic core, in advanced
lesions (56). Recent data from several laboratories suggest that
O 2 is produced by the endothelium in hypercholesterolemic
rabbit aorta (57) and by medial and adventitial SMC in normal rabbit
aorta (58). Detectable levels of ceruloplasmin in human atherosclerotic
lesions have been reported (59, 60). However, the structural integrity,
localization, and source of ceruloplasmin in the vessel wall are not
known. EC-mediated uptake from the plasma compartment is one possible
source, as is synthesis and secretion by vascular cells. Consistent
with the latter mechanism, Fleming et al. (61) have shown
that cytokine-stimulated pulmonary macrophages in vitro
express the ceruloplasmin gene and synthesize and secrete the protein.
There are not any published reports showing production of ceruloplasmin
by EC or SMC, and the presence of ceruloplasmin in vessel wall regions
adjacent to these cell types has not been examined.
There is no direct evidence that ceruloplasmin expresses oxidant
activity in vivo. However, according to a recent report
comparing ``oxidation-related'' serum constituents with serum lipid
oxidation levels by multivariate analysis, the strongest association
was found for ceruloplasmin (62). Furthermore, plasma ceruloplasmin
levels are elevated in patients with vascular diseases including
abdominal aortic aneurysms, vasculitis, and peripheral arterial disease
(63, 64). Although these correlations may be a noncausative result of
an accompanying acute phase response, case-control studies also show
serum ceruloplasmin is a risk factor for coronary heart disease (65,
66). The recent discovery of patients with mutations in the
ceruloplasmin gene and consequent ``aceruloplasminemia'' (67, 68, 69) may
provide insights into the role of ceruloplasmin in vascular disease
onset and progression. However, severe complications including
pathologic iron accumulation and diabetes may obfuscate any direct role
of ceruloplasmin. Studies using transgenic animals lacking specific
functional domains of ceruloplasmin, e.g., the putative
``oxidant activity domain,'' may be necessary to elucidate the role
of the protein in lipid and lipoprotein oxidation processes in
vivo.
FOOTNOTES
*
This work was supported by Grants HL29582 and HL52692 and by
a Minority Supplement Award (to E. E.) from the National Heart Lung and
Blood Institute, National Institutes of Health, by a grant-in-aid from
the American Heart Association of Northeast Ohio, and by an Established
Investigator Award of the American Heart Association. The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
``advertisement'' in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Cell Biology,
Cleveland Clinic Research Inst., 9500 Euclid Ave., Cleveland, OH 44195. Tel.: 216-444-8053; Fax: 216-444-9404.
1
The abbreviations used are: LDL, low density
lipoprotein; EC, endothelial cells; LPDS, lipoprotein-deficient serum;
SMC, smooth muscle cells; SOD, superoxide dismutase; TBARS,
thiobarbituric acid-reacting substances.
Acknowledgments
We gratefully acknowledge helpful discussions
with Drs. Martha Cathcart, Guy Chisolm, Barsanjit Mazumder, and
Gurunathan Murugesan and the expert technical assistance of Alan
Prok.
REFERENCES
-
Ylä-Herttuala, S.
(1991)
Ann. Med.
23,
561-567
[Medline]
[Order article via Infotrieve]
-
Henriksen, T.,
Mahoney, E. M.,
Steinberg, D.
(1983)
Arteriosclerosis
3,
149-159
[Abstract/Free Full Text]
-
Quinn, M. T.,
Parthasarathy, S.,
Fong, L. G.,
Steinberg, D.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
2995-2998
[Abstract/Free Full Text]
-
Navab, M.,
Imes, S. S.,
Hama, S. Y.,
Hough, G. P.,
Ross, L. A.,
Bork, R. W.,
Valente, A. J.,
Berliner, J. A.,
Drinkwater, D. C.,
Laks, H.,
Fogelman, A. M.
(1991)
J. Clin. Invest.
88,
2039-2046
-
Berliner, J. A.,
Territo, M. C.,
Sevanian, A.,
Ramin, S.,
Kim, J. A.,
Bamshad, B.,
Esterson, M.,
Fogelman, A. M.
(1990)
J. Clin. Invest.
85,
1260-1266
-
Chisolm, G. M., and Penn, M. S. (1995) in Atherosclerosis and
Coronary Artery Disease (Fuster, V., Ross, R., and Topol, E., eds)
Raven Press, Ltd., New York
-
Autio, I.,
Jaakkola, O.,
Solakivi, T.,
Nikkari, T.
(1990)
FEBS Lett.
277,
247-249
[CrossRef][Medline]
[Order article via Infotrieve]
-
Murugesan, G.,
Chisolm, G. M.,
Fox, P. L.
(1993)
J. Cell Biol.
120,
1011-1019
[Abstract/Free Full Text]
-
Ylä-Herttuala, S.,
Palinski, W.,
Rosenfeld, M. E.,
Parthasarathy, S.,
Carew, T. E.,
Butler, S.,
Witztum, J. L.,
Steinberg, D.
(1989)
J. Clin. Invest.
84,
1086-1095
-
Hoff, H. F.,
O'Neil, J.
(1991)
Arterioscler. Thromb.
11,
1209-1222
[Abstract/Free Full Text]
-
Morel, D. W.,
DiCorleto, P. E.,
Chisolm, G. M.
(1984)
Arteriosclerosis
4,
357-364
[Abstract/Free Full Text]
-
Steinbrecher, U. P.,
Parthasarathy, S.,
Leake, D. S.,
Witztum, J. L.,
Steinberg, D.
(1984)
Proc. Natl. Acad. Sci. U. S. A.
81,
3883-3887
[Abstract/Free Full Text]
-
Heinecke, J. W.,
Rosen, H.,
Chait, A.
(1984)
J. Clin. Invest.
74,
1890-1894
-
Cathcart, M. K.,
Morel, D. W.,
Chisolm, G. M.
(1985)
J. Leukocyte Biol.
38,
341-350
[Abstract]
-
Parthasarathy, S.,
Printz, D. J.,
Boyd, D.,
Joy, L.,
Steinberg, D.
(1986)
Arteriosclerosis
6,
505-510
[Abstract/Free Full Text]
-
Hiramatsu, K.,
Rosen, H.,
Heinecke, J. W.,
Wolfbauer, G.,
Chait, A.
(1987)
Arteriosclerosis
7,
55-60
[Abstract]
-
Heinecke, J. W.,
Rosen, H.,
Suzuki, L. A.,
Chait, A.
(1987)
J. Biol. Chem.
262,
10098-10103
[Abstract/Free Full Text]
-
Steinbrecher, U. P.
(1988)
Biochim. Biophys. Acta
959,
20-30
[Medline]
[Order article via Infotrieve]
-
Cathcart, M. K.,
McNally, A. K.,
Morel, D. W.,
Chisolm, G. M.
(1989)
J. Immunol.
142,
1963-1969
[Abstract]
-
Parthasarathy, S.,
Wieland, E.,
Steinberg, D.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
1046-1050
[Abstract/Free Full Text]
-
Jessup, W.,
Simpson, J. A.,
Dean, R. T.
(1993)
Atherosclerosis
99,
107-120
[CrossRef][Medline]
[Order article via Infotrieve]
-
Halliwell, B.,
Gutteridge, J. M. C.
(1990)
Methods Enzymol.
186,
1-85
[CrossRef][Medline]
[Order article via Infotrieve]
-
Abdalla, D. S. P.,
Campa, A.,
Monteiro, H. P.
(1992)
Atherosclerosis
97,
149-159
[CrossRef][Medline]
[Order article via Infotrieve]
-
Balla, G.,
Jacob, H. S.,
Eaton, J. W.,
Belcher, J. D.,
Vercellotti, G. M.
(1991)
Arterioscler. Thromb.
11,
1700-1711
[Abstract/Free Full Text]
-
Lamb, D. J.,
Leake, D. S.
(1994)
FEBS Lett.
352,
15-18
[CrossRef][Medline]
[Order article via Infotrieve]
-
Wieland, E.,
Parthasarathy, S.,
Steinberg, D.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
5929-5933
[Abstract/Free Full Text]
-
Heinecke, J. W.,
Li, W.,
Francis, G. A.,
Goldstein, J. A.
(1993)
J. Clin. Invest.
91,
2866-2872
-
Ehrenwald, E.,
Fox, P. L.
(1994)
Arch. Biochem. Biophys.
309,
392-395
[CrossRef][Medline]
[Order article via Infotrieve]
-
Ehrenwald, E.,
Chisolm, G. M.,
Fox, P. L.
(1994)
J. Clin. Invest.
93,
1493-1501
-
Lamb, D. J.,
Leake, D. S.
(1994)
FEBS Lett.
338,
122-126
[CrossRef][Medline]
[Order article via Infotrieve]
-
Swain, J. A.,
Darley-Usmar, V.,
Gutteridge, J. M. C.
(1994)
FEBS Lett.
342,
49-52
[CrossRef][Medline]
[Order article via Infotrieve]
-
Rydén, L.
(1984)
Copper Proteins and Copper Enzymes
(Lontie, R.,
eds)
, Vol III, p. 37, CRC Press
Inc., Boca Raton,
FL
-
Fox, P. L.,
Mukhopadhyay, C.,
Ehrenwald, E.
(1995)
Life Sci.
56,
1749-1758
[CrossRef][Medline]
[Order article via Infotrieve]
-
Messerschmidt, A.,
Huber, R.
(1990)
Eur. J. Biochem.
187,
341-352
[Medline]
[Order article via Infotrieve]
-
Sunderman, F. W.,
Nomoto, S.
(1970)
Clin. Chem.
16,
903-910
[Abstract]
-
Fox, P. L.,
DiCorleto, P. E.
(1984)
J. Cell. Physiol.
121,
298-308
[CrossRef][Medline]
[Order article via Infotrieve]
-
Ross, R.
(1971)
J. Cell Biol.
50,
172-186
[Abstract/Free Full Text]
-
Hessler, J. R.,
Morel, D. W.,
Lewis, L. J.,
Chisolm, G. M.
(1983)
Arteriosclerosis
3,
215-222
[Abstract/Free Full Text]
-
Esterbauer, H.,
Striegl, G.,
Puhl, H.,
Rothender, M.
(1989)
Free Radical Res. Commun.
6,
67-75
[Medline]
[Order article via Infotrieve]
-
El-Saadani, M.,
Esterbauer, H.,
El-Sayed, M.,
Goher, M.,
Nassar, A. Y.,
Jürgens, G.
(1989)
J. Lipid Res.
30,
627-630
[Abstract]
-
Nakamura, K.,
Handa, S.
(1984)
Anal. Biochem.
142,
406-410
[CrossRef][Medline]
[Order article via Infotrieve]
-
Heinecke, J. W.,
Baker, L.,
Rosen, H.,
Chait, A.
(1986)
J. Clin. Invest.
77,
757-761
-
Heery, J. M.,
Kozak, M.,
Stafforini, D. M.,
Jones, D. A.,
Zimmerman, G.
A.,
McIntyre, T. M.,
Prescott, S. M.
(1995)
J. Clin. Invest.
96,
2322-2330
-
Kalant, N.,
McCormick, S.
(1992)
Biochim. Biophys. Acta
1128,
211-219
[Medline]
[Order article via Infotrieve]
-
Dabbagh, A. J.,
Frei, B.
(1995)
J. Clin. Invest.
96,
1958-1966
-
Kelner, M. J.,
Bagnell, R.,
Welch, K. J.
(1990)
J. Biol. Chem.
265,
1306-1311
[Abstract/Free Full Text]
-
Savenkova, M. I.,
Mueller, D. M.,
Heinecke, J. W.
(1994)
J. Biol. Chem.
269,
20394-20400
[Abstract/Free Full Text]
-
Thomas, C. E.
(1992)
Biochim. Biophys. Acta
1128,
50-57
[Medline]
[Order article via Infotrieve]
-
Heinecke, J. W.,
Kawamura, M.,
Suzuki, L.,
Chait, A.
(1993)
J. Lipid Res.
34,
2051-2061
[Abstract]
-
Parthasarathy, S. (1994) Modified Lipoproteins in the
Pathogenesis of Atherosclerosis, Chapter 5, pp. 91-119, R. G. Landes, Austin, TX
-
van Hinsbergh, V. W.,
Scheffer, M.,
Havekes, L.,
Kempen, H. J.
(1986)
Biochim. Biophys. Acta
878,
49-64
[Medline]
[Order article via Infotrieve]
-
Biemond, P.,
Van Eijk, H. G.,
Swaak, A. J.,
Koster, J. F.
(1984)
J. Clin. Invest.
73,
1576-1579
-
Thomas, C. E.,
Morehouse, L. A.,
Aust, S. D.
(1985)
J. Biol. Chem.
260,
3275-3280
[Abstract/Free Full Text]
-
Svingen, B. A.,
Buege, J. A.,
O'Neal, F. O.,
Aust, S. D.
(1979)
J. Biol. Chem.
254,
5892-5899
[Abstract/Free Full Text]
-
Czapski, G.,
Goldstein, S.,
Meyerstein, D.
(1988)
Free Radical Res. Commun.
4,
231-236
[Medline]
[Order article via Infotrieve]
-
Rosenfeld, M. E.,
Palinski, W.,
Ylä-Herttuala, S.,
Butler, S.,
Witztum, J. L.
(1990)
Arteriosclerosis
10,
336-349
[Abstract/Free Full Text]
-
Ohara, Y.,
Peterson, T. E.,
Harrison, D. G.
(1993)
J. Clin. Invest.
91,
2546-2551
-
Pagano, P. J.,
Ito, Y.,
Tornheim, K.,
Gallop, P. M.,
Tauber, A. I.,
Cohen, R. A.
(1995)
Am. J. Physiol.
268,
H2274-H2280
-
Hollander, W.,
Colombo, M. A.,
Kirkpatrick, B.,
Paddock, J.
(1979)
Atherosclerosis
34,
391-405
[CrossRef][Medline]
[Order article via Infotrieve]
-
Swain, J.,
Gutteridge, J. M. C.
(1995)
FEBS Lett.
368,
513-515
[CrossRef][Medline]
[Order article via Infotrieve]
-
Fleming, R. E.,
Whitman, I. P.,
Gitlin, J. D.
(1991)
Am. J. Physiol.
260,
L68-L74
-
Craig, W. Y.,
Poulin, S. E.,
Palomaki, G. E.,
Neveux, L. M.,
Ritchie, R. F.,
Ledue, T. B.
(1995)
Arterioscler. Thromb. Vasc. Biol.
15,
733-739
[Abstract/Free Full Text]
-
Powell, J. T.,
Muller, B. R.,
Greenhalgh, R. M.
(1987)
J. Cardiovasc. Surg.
28,
528-530
[Medline]
[Order article via Infotrieve]
-
Belch, J. J.,
Chopra, M.,
Hutchison, S.,
Lorimer, R.,
Sturrock, R. D.,
Forbes, C. D.,
Smith, W. E.
(1989)
Free Radical Biol. Med.
6,
375-378
[CrossRef][Medline]
[Order article via Infotrieve]
-
Reunanen, A.,
Knekt, P.,
Aaran, R. -K.
(1992)
Am. J. Epidemiol.
136,
1082-1090
[Abstract/Free Full Text]
-
Mänttäri, M.,
Manninen, V.,
Huttunen, J. K.,
Palosuo, T.,
Ehnholm, C.,
Heinonen, O. P.,
Frick, M. H.
(1994)
Eur. Heart J.
15,
1599-1603
[Abstract/Free Full Text]
-
Logan, J. I.,
Harveyson, K. B.,
Wisdom, G. B.,
Hughes, A. E.,
Archbold, G. P. R.
(1994)
Q. J. Med.
87,
663-670
[Abstract/Free Full Text]
-
Harris, Z. L.,
Takahashi, Y.,
Miyajima, H.,
Serizawa, M.,
MacGillivray, R. T. A.,
Gitlin, J. D.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
2539-2543
[Abstract/Free Full Text]
-
Yoshida, K.,
Furihata, K.,
Takeda, S.,
Nakamura, A.,
Yamamoto, K.,
Morita, H.,
Hiyamuta, S.,
Ikeda, S.,
Shimizu, N.,
Yanagisawa, N.
(1995)
Nat. Genet.
9,
267-272
[CrossRef][Medline]
[Order article via Infotrieve]
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
N. Tapryal, C. Mukhopadhyay, D. Das, P. L. Fox, and C. K. Mukhopadhyay
Reactive Oxygen Species Regulate Ceruloplasmin by a Novel mRNA Decay Mechanism Involving Its 3'-Untranslated Region: IMPLICATIONS IN NEURODEGENERATIVE DISEASES
J. Biol. Chem.,
January 16, 2009;
284(3):
1873 - 1883.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Stocker and J. F. Keaney Jr.
Role of Oxidative Modifications in Atherosclerosis
Physiol Rev,
October 1, 2004;
84(4):
1381 - 1478.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Voziyan, R. G. Khalifah, C. Thibaudeau, A. Yildiz, J. Jacob, A. S. Serianni, and B. G. Hudson
Modification of Proteins In Vitro by Physiological Levels of Glucose: PYRIDOXAMINE INHIBITS CONVERSION OF AMADORI INTERMEDIATE TO ADVANCED GLYCATION END-PRODUCTS THROUGH BINDING OF REDOX METAL IONS
J. Biol. Chem.,
November 21, 2003;
278(47):
46616 - 46624.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-L. Sentman, T. Brannstrom, S. Westerlund, M. O. Laukkanen, S. Yla-Herttuala, S. Basu, and S. L. Marklund
Extracellular Superoxide Dismutase Deficiency and Atherosclerosis in Mice
Arterioscler. Thromb. Vasc. Biol.,
September 1, 2001;
21(9):
1477 - 1482.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Exner, M. Hermann, R. Hofbauer, S. Kapiotis, P. Quehenberger, W. Speiser, I. Held, and B. M.K Gmeiner
Semicarbazide-sensitive amine oxidase catalyzes endothelial cell-mediated low density lipoprotein oxidation
Cardiovasc Res,
June 1, 2001;
50(3):
583 - 588.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Mazumder and P. L. Fox
Delayed Translational Silencing of Ceruloplasmin Transcript in Gamma Interferon-Activated U937 Monocytic Cells: Role of the 3' Untranslated Region
Mol. Cell. Biol.,
October 1, 1999;
19(10):
6898 - 6905.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. M. Chisolm III, S. L. Hazen, P. L. Fox, and M. K. Cathcart
The Oxidation of Lipoproteins by Monocytes-Macrophages. BIOCHEMICAL AND BIOLOGICAL MECHANISMS
J. Biol. Chem.,
September 10, 1999;
274(37):
25959 - 25962.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Kennedy, A. J. Ghio, W. Reed, J. Samet, J. Zagorski, J. Quay, J. Carter, L. Dailey, J. R. Hoidal, and R. B. Devlin
Copper-dependent Inflammation and Nuclear Factor-kappa B Activation by Particulate Air Pollution
Am. J. Respir. Cell Mol. Biol.,
September 1, 1998;
19(3):
366 - 378.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
N. Inoue, S. Kawashima, K.-I. Hirata, Y. Rikitake, S. Takeshita, W. Yamochi, H. Akita, and M. Yokoyama
Stretch force on vascular smooth muscle cells enhances oxidation of LDL via superoxide production
Am J Physiol Heart Circ Physiol,
June 1, 1998;
274(6):
H1928 - H1932.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. K. Mukhopadhyay, B. Mazumder, P. F. Lindley, and P. L. Fox
Identification of the prooxidant site of human ceruloplasmin: A model for oxidative damage by copper bound to protein surfaces
PNAS,
October 14, 1997;
94(21):
11546 - 11551.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1996 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|